XXXX reduces the @entity190 and blood transfusion requirements following peri-acetabular osteotomy.

@entity1 @entity190 @entity928 @entity927 @entity1211
We have investigated the effect of using @entity927 ( @entity928 ) during peri-acetabular osteotomy (PAO) on peri-operative @entity190 and blood transfusion requirements. In addition we analysed whether the use of @entity928 was associated with an increased risk of @entity1211 ( @entity1211 ) following this procedure. A consecutive series of 96 PAOs, performed by a single surgeon, were reviewed. A total of 48 @entity1 received @entity928 and 48 did not. The @entity928 group received a continuous infusion of @entity928 at a rate of 10 mg/kg/h. The primary outcome measure was the requirement for blood transfusion. Secondary outcomes included @entity190 , the decrease in the level of haemoglobin in the blood, the length of hospital stay, and the complications of this treatment. The mean rate of transfusion was significantly lower in the @entity928 group (62.5% vs 12.5%, p  < 0.001). The mean @entity190 was also significantly reduced in the @entity928 group (1.9 L (standard deviation (sd) 0.9) vs 1.5 L (sd 0.7), p < 0.01). No post-operative episodes of @entity1211 were identified in either group. The use of @entity928 reduced the @entity190 and the rate of transfusion after PAO significantly, without adverse effects such as an increased rate of @entity1211 . Cite this article: Bone Joint J 2015;97-B:1604-7.
